{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:48:22Z","timestamp":1781282902762,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40290-023-00474-y","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T16:01:51Z","timestamp":1683216111000},"page":"265-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Embedding Patient-Centricity by Collaborating with Patients to Transform the Rare Disease Ecosystem"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6361-0004","authenticated-orcid":false,"given":"Rohita","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaira","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Campagnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendi","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lelainia","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"474_CR1","unstructured":"WHO. Patient Engagement: Technical Series on Safer Primary Care. 2016 [cited 2022 10 May]; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/252269\/9789241511629-eng.pdf;sequence=1?msclkid=aca9d8afd03a11ec9e5780c6fbb59d2c"},{"issue":"3","key":"474_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1369-7625.2007.00450.x","volume":"10","author":"RE Davis","year":"2007","unstructured":"Davis RE, Jacklin R, Sevdalis N, Vincent CA. Patient involvement in patient safety: what factors influence patient participation and engagement? Health Expect. 2007;10(3):259\u201367.","journal-title":"Health Expect"},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40900-018-0093-3","volume":"4","author":"M Chalasani","year":"2018","unstructured":"Chalasani M, Vaidya P, Mullin T. Enhancing the incorporation of the patient\u2019s voice in drug development and evaluation. Res Involv Engagem. 2018;4:1\u201310.","journal-title":"Res Involv Engagem."},{"issue":"1","key":"474_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40900-021-00253-6","volume":"7","author":"N Hamakawa","year":"2021","unstructured":"Hamakawa N, Kogetsu A, Isono M, Yamasaki C, Manabe S, Takeda T, et al. The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN project. Res Involv Engagem. 2021;7(1):1\u201315.","journal-title":"Res Involv Engagem."},{"issue":"2","key":"474_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1136\/bmjinnov-2016-000157","volume":"3","author":"G Yeoman","year":"2017","unstructured":"Yeoman G, Furlong P, Seres M, Binder H, Chung H, Garzya V, et al. Defining patient centricity with patients for patients and caregivers: a collaborative endeavour. BMJ Innov. 2017;3(2):76\u201383.","journal-title":"BMJ Innov."},{"key":"474_CR6","first-page":"1","volume":"42","author":"JH Benbow","year":"2022","unstructured":"Benbow JH, Rivera DR, Lund JL, Feldman JE, Kim ES. Increasing Inclusiveness of patient-centric clinical evidence generation in oncology: real-world data and clinical trials. Am Soc Clin Oncol Educ Book. 2022;42:1\u201311.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"474_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12655","volume":"6","author":"JC Roberts","year":"2022","unstructured":"Roberts JC, Recht M, Gonzales SE, Stanley J, Denne M, Caicedo J, et al. Incorporating the patient voice and patient engagement in GOAL-H\u0113m: advancing patient-centric hemophilia care. Res Pract Thromb Haemost. 2022;6(1): e12655.","journal-title":"Res Pract Thromb Haemost."},{"issue":"6","key":"474_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1177\/2168479015580384","volume":"49","author":"A Hoos","year":"2015","unstructured":"Hoos A, Anderson J, Boutin M, Dewulf L, Geissler J, Johnston G, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929\u201339.","journal-title":"Ther Innov Regul Sci."},{"issue":"sup1","key":"474_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/13814788.2015.1043729","volume":"21","author":"H Trier","year":"2015","unstructured":"Trier H, Valderas JM, Wensing M, Martin HM, Egebart J. Involving patients in patient safety programmes: a scoping review and consensus procedure by the LINNEAUS collaboration on patient safety in primary care. Eur J Gen Pract. 2015;21(sup1):56\u201361.","journal-title":"Eur J Gen Pract."},{"issue":"1","key":"474_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02286-w","volume":"17","author":"R Francisco","year":"2022","unstructured":"Francisco R, Brasil S, Pascoal C, Jaeken J, Liddle M, Videira PA, et al. The road to successful people-centric research in rare diseases: the web-based case study of the Immunology and Congenital Disorders of Glycosylation questionnaire (ImmunoCDGQ). Orphanet J Rare Dis. 2022;17(1):1\u201317.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"474_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13023-017-0718-x","volume":"12","author":"T Morel","year":"2017","unstructured":"Morel T, Cano SJ. Measuring what matters to rare disease patients\u2014reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet J Rare Dis. 2017;12(1):171.","journal-title":"Orphanet J Rare Dis"},{"key":"474_CR12","unstructured":"EUMA. European Union Medicines Agency Network Strategy to 2020. Working together to improve health. . 2015 [cited 2022 10 May]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/eu-medicines-agencies-network-strategy-2020-working-together-improve-health_en.pdf"},{"key":"474_CR13","unstructured":"Shire. Rare disease impact report: insights from patients and the medical community. 2013; Available from: https:\/\/globalgenes.org\/wp-content\/uploads\/2013\/04\/ShireReport-1.pdf"},{"key":"474_CR14","unstructured":"Dunoyer M. Rare disease inequities: Opportunities for change. Fortune."},{"issue":"1","key":"474_CR15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13023-018-0936-x","volume":"13","author":"P Kaufmann","year":"2018","unstructured":"Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases\u2014the view from the national center for advancing translational sciences\u2014office of rare diseases research. Orphanet J Rare Dis. 2018;13(1):196.","journal-title":"Orphanet J Rare Dis."},{"key":"474_CR16","doi-asserted-by":"crossref","unstructured":"Wilson P, Mathie E, Keenan J, McNeilly E, Goodman C, Howe A, et al. Health Services and Delivery Research. ReseArch with Patient and Public invOlvement: a RealisT evaluation\u2014the RAPPORT study. Southampton (UK): NIHR Journals Library; 2015.","DOI":"10.3310\/hsdr03380"},{"issue":"5","key":"474_CR17","first-page":"279","volume":"36","author":"T Flatau","year":"2022","unstructured":"Flatau T, Greenfield J, Dickie B, Rayner O, Matthews H, Wise J. Medical research charities and biopharmaceutical companies as partners in patient-centred R&D. Pharmaceut Med. 2022;36(5):279\u201386.","journal-title":"Pharmaceut Med."},{"key":"474_CR18","unstructured":"FDA. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. 2022 [cited 2022 30 July]; Available from: https:\/\/www.fda.gov\/media\/131230\/download"},{"issue":"11","key":"474_CR19","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843\u201354.","journal-title":"J Clin Invest"},{"issue":"2","key":"474_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1556\/EuJMI.2.2012.2.2","volume":"2","author":"PN Nesargikar","year":"2012","unstructured":"Nesargikar PN, Spiller B, Chavez R. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol (Bp). 2012;2(2):103\u201311.","journal-title":"Eur J Microbiol Immunol (Bp)."},{"issue":"18","key":"474_CR21","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311.","journal-title":"Blood"},{"issue":"2","key":"474_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3346\/jkms.2016.31.2.214","volume":"31","author":"JH Jang","year":"2016","unstructured":"Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, Jo DY, et al. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH Registry. J Korean Med Sci. 2016;31(2):214\u201321.","journal-title":"J Korean Med Sci"},{"issue":"9","key":"474_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"19","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflam. 2012;19(9):14.","journal-title":"J Neuroinflam"},{"issue":"9","key":"474_CR24","volume":"10","author":"E van der Vinne","year":"2009","unstructured":"van der Vinne E. The ultimate goal of disease management: improved quality of life by patient centric care. Int J Integr Care. 2009;10(9): e89.","journal-title":"Int J Integr Care"},{"issue":"1","key":"474_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.4103\/2230-8210.107875","volume":"17","author":"J Bhutani","year":"2013","unstructured":"Bhutani J, Bhutani S, Kumar J. Patient-centric care: managing celiac disease. Indian J Endocrinol Metab. 2013;17(1):177.","journal-title":"Indian J Endocrinol Metab."},{"issue":"4","key":"474_CR26","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/S2214-109X(14)70198-6","volume":"2","author":"M Pai","year":"2014","unstructured":"Pai M, Yadav P, Anupindi R. Tuberculosis control needs a complete and patient-centric solution. Lancet Glob Health. 2014;2(4):e189\u201390.","journal-title":"Lancet Glob Health"},{"issue":"Suppl 2","key":"474_CR27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/eye.2012.32","volume":"26","author":"CS Brand","year":"2012","unstructured":"Brand CS. Management of retinal vascular diseases: a patient-centric approach. Eye (Lond). 2012;26(Suppl 2):S1-16.","journal-title":"Eye (Lond)."},{"issue":"6","key":"474_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.2217\/bmm.11.78","volume":"5","author":"SA Waldman","year":"2011","unstructured":"Waldman SA, Terzic A. Patient-centric clinical pharmacology advances the path to personalized medicine. Biomark Med. 2011;5(6):697\u2013700.","journal-title":"Biomark Med"},{"key":"474_CR29","unstructured":"Goler Blount L. Historical discrimination, malpractice and lingering mistrust block the path to significant diversity in rare disease research. Diversity Elusive in Rare Disease Research [Briefings for Journalists] 2021 20\/12\/2021 [cited 2022 3 August]; Available from: https:\/\/nationalpress.org\/topic\/diversity-elusive-in-rare-disease-research\/"},{"issue":"6","key":"474_CR30","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1111\/cts.13105","volume":"14","author":"SM Abdel-Rahman","year":"2021","unstructured":"Abdel-Rahman SM, Wimes MP, Curran T. A call to action: issuing a diversity and inclusion challenge to research organizations. Clin Transl Sci. 2021;14(6):2095\u20138.","journal-title":"Clin Transl Sci"},{"key":"474_CR31","unstructured":"FDA. Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials\u201d Guidance for Industry Draft Guidance. 2022 14\/04\/2022 [cited 2022 4 August]; Available from: https:\/\/www.regulations.gov\/document\/FDA-2021-D-0789-0002"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00474-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-023-00474-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00474-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T16:20:04Z","timestamp":1688228404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-023-00474-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1007\/s40290-023-00474-y","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"14 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All activities and analysis were funded by Alexion, AstraZeneca Rare Disease. Medical writing and editorial support, funded by Alexion, AstraZeneca Rare Disease, was provided by Catherine Hoare, PhD, Bioscript Medical, Macclesfield, UK. Alexion, AstraZeneca Rare Disease reviewed and provided feedback on the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rohita Sharma and Judy Campagnari are employees of, and hold stocks in, Alexion, AstraZeneca Rare Disease. Judy Campagnari also has patents pending. Lelainia Lloyd has been the recipient of grants, honoraria, support for attending meetings and equipment, materials, drugs, medical writing, gifts or other services from Alexion, AstraZeneca Rare Disease; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid from the MS Society of Canada; and is on the editorial board for the Journal of Medical Imaging and Radiation Sciences. Sumaira Ahmed and Wendi Huff have no competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to drafting and revising the article, provided their final approval of all content and agree to be accountable for all aspects of the work. Yiyi Xia (Director, STAR Ideation & Strategy at Alexion, AstraZeneca Rare Disease) contributed to the initial stages of the article and provided key information.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}